Released on: June 10, 2008, 2:28 pm

Press Release Author: GTCbio

Industry: Biotech

Press Release Summary: Alain Delcayre, Director of Research at BN ImmunoTherapeutics
will Present at GTCbio's 2nd Protein Therapeutics Discovery & Development Conference
on September 8-9, 2008 in San Diego, CA

Press Release Body: MONROVIA, CA - Dr. Alain Delcayre, Director of Research at BN
ImmunoTherapeutics will be speaking at GTCbio's 2nd Protein Therapeutics Discovery &
Development conference on September 8-9, 2008 in San Diego, CA. Dr. Gonzalez will
present on recombinant protein design for the generation of particle-bound and
targeted therapeutics using natural and synthetic vesicles as delivery vehicles.
The pharmacodynamic properties of therapeutics are critical parameters that
contribute to drug efficacy. They have significant bearing on the determination of
treatment regimen and doses and consequently also affect benefit/safety ratio as
well as cost of treatment. Drug features leading to improved efficacy include
particle-bound formulation, which can increase the stability /half life of
compounds, and targeted delivery. In addition to improving efficacy, these features
may contribute to achieve clinical benefits using lower drug doses, thereby
potentially limiting drug-related side effects. BN ImmunoTherapeutics has developed
a technology called Exosome Display that enable the manipulation of the protein
content of naturally occurring exosomal vesicles as well as the efficient loading of
synthetic vesicles with therapeutic protein and/or ligand for targeted delivery of
therapeutic compounds.

GTCbio's 2nd Annual Protein Therapeutics Discovery and Development Conference will
explore the therapeutic applications of proteins, with a look at discovery and
design of therapeutics, overcoming challenges associated with protein based drugs,
and new tools and strategies in process development. Finally, attendees will get an
update on novel developments in protein therapeutics. The keynote presentation will
be given by Dr. Michael Hanley, Vice President of Discovery Research & CSO of Amylin
Pharmaceuticals.

For more information including a detailed agenda, exhibitor opportunities and
registration information visit http://gtcbio.com/conferenceDetails.aspx?id=128.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.


Web Site: http://www.gtcbio.com

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax,
Jason.yi@gtcbo.com
434 W. Foothill Blvd.
Monrovia, CA 91016